dasatinib / Generic mfg. - LARVOL DELTA

The role of disulfidptosis-driven tumor microenvironment remodeling in pancreatic cancer progression. (PubMed, Front Immunol) - "It informed personalized treatment strategies, revealing differential sensitivity to therapeutic agents including dasatinib and UMI-77...Integrated multi-omics analyses reveal a strong association between disulfidptosis and an immunosuppressive tumor microenvironment, positioning it as a candidate metabolic vulnerability that warrants further functional investigation. These findings offer correlative insights into the involvement of disulfidptosis in immune regulation and suggest that further exploration of this pathway may inform future immunotherapeutic strategies."

Biomarker • IO biomarker • Journal • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • CD8

KQB198-102: A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies (clinicaltrials.gov) - P1 | N=13 | Active, not recruiting | Sponsor: Kumquat Biosciences Inc. | Recruiting ➔ Active, not recruiting | N=122 ➔ 13 | Trial completion date: Feb 2028 ➔ Mar 2027 | Trial primary completion date: Aug 2027 ➔ Mar 2027

Enrollment change • Enrollment closed • Monotherapy • Trial completion date • Trial primary completion date • Hematological Malignancies • Oncology

CMLXI: Frontline Asciminib Combination in Chronic Phase CML (clinicaltrials.gov) - P2 | N=125 | Active, not recruiting | Sponsor: University of Jena | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • BCR

ASIM-POST Ph+: Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML (clinicaltrials.gov) - P2 | N=45 | Not yet recruiting | Sponsor: The University of Hong Kong

New P2 trial • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • Transplantation

EFFECTS OF SENOLYTIC DRUGS ON KIDNEY TISSUE IN AGED MICE (ISN-WCN 2026) - "This study aimed to examine how the senolytic drugs dasatinib and quercetin (DQ), known for their rejuvenating properties, influence the expression of inflammation- and fibrosis-related genes in the kidneys of aged mice.Methods Mice were divided into five groups based on age and treatment with or without DQ administration: Young mice (4–6 months old); Aged mice (23–24 months old, n=10); DQ-treated Aged mice (Aged+DQ, 23–24 months old); Old mice (26–30 months old); and DQ-treated Old mice (Old+DQ, 26–30 months old)...Comprehensive analysis suggests that suppression of inflammation is a principal mechanism underlying the renoprotective action of senolytic drugs. The reduction of inflammatory cytokine secretion appears to be a key process contributing to the kidney-protective effects of DQ."

Preclinical • Fibrosis • Immunology • Inflammation • Renal Disease • CCL7 • MMP7

SYMPTOMATIC RECURRENT BILATERAL PLEURAL EFFUSIONS REQUIRING REPEATED THERAPEUTIC THORACENTESIS IN ESRD ON MAINTENANCE HEMODIALYSIS: IS THIS PULMONARY HYPERTESNION, HYPERVOLEMIA OR IS IT DASATINIB-ASSOCIATED ADVERSE REACTION? (ISN-WCN 2026) - "He had responded to imatinib, a TKI, and was in remission while on Imatinib through 2016-2017. As at last review in early August 2025, the patient is feeling better, much improved, not short of breath, and no longer confused. This is a lesson for providers when considering adverse drug reactions and the timing of drug initiation."

Clinical • Pleural effusion • Atrial Fibrillation • Chronic Kidney Disease • Chronic Myeloid Leukemia • Congestive Heart Failure • Heart Failure • Hematological Malignancies • Hepatology • Infectious Disease • Leukemia • Pneumonia • Pulmonary Arterial Hypertension • Pulmonary Disease • Renal Disease • Respiratory Diseases • ABL1 • BCR

Outcomes of Patients Treated With Dasatinib 50 mg/d: A Pooled Analysis. (PubMed, Clin Lymphoma Myeloma Leuk) - "The long-term follow-up confirms the safety and efficacy of dasatinib 50 mg/d in patients with newly diagnosed CML-CP."

Journal • Retrospective data • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • Respiratory Diseases

The oncogenic EGFR-SHC1 fusion confers insensitivity to EGFR-TKI via dual activation of N-EGFR kinase domain and C-SHC1 phosphorylation sites in lung cancer. (PubMed, Cancer Discov) - "Notably, dual-targeted inhibition using afatinib (EGFR-TKI) in combination with dasatinib (SRC-TKI) induced marked tumor regression in a TKI-refractory NSCLC patient with EGFR-SHC1. This study illustrates a cooperative oncogenesis between kinase and scaffold protein in fusions, providing a clinically actionable strategy for overcoming TKI resistance in patients with these oncogenic fusions."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Neoadjuvant Antiandrogen Therapy With or Without MEK or SRC Inhibition for Unfavorable-risk Prostate Cancer: A Phase 2 Randomized Clinical Trial. (PubMed, Eur Urol Oncol) - "Neoadjuvant SRC or MEK inhibition does not appear to mitigate the EMT response to ADT or influence clinical or pathological outcomes."

Clinical • Journal • P2 data • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor • CDH2 • MAP2K1 • MAP2K2 • VIM

Reduced fertility induced by MASLD in female mice is improved by Senolytic treatment. (PubMed, Biol Reprod) - "Starting at six months of age, mice were also randomized to receive senolytic treatment (Dasatinib + Quercetin, D + Q) or vehicle within each diet...Mice with MASLD had increased ovarian senescence, inflammation, and fibrosis, which was attenuated by senolytic treatment, despite having no effect on the ovarian follicle reserve. We conclude that senolytic treatment has potential for improving reproductive function in aged female mice with MASLD, despite limited impact in liver and systemic indicators."

Journal • Preclinical • Fibrosis • Hepatology • Immunology • Inflammation • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease

From Molecular Silence to Lymphoid Blast Phase: Diagnostic and Therapeutic Challenges in a Young Female Patient With Chronic Myeloid Leukemia. (PubMed, Cureus) - "Notably, during treatment with tyrosine kinase inhibitors (TKIs), she became intolerant to first- and second-generation TKIs, including the branded and generic imatinib, nilotinib, and dasatinib, followed by progression into lymphoid blast phase. This case highlights the diagnostic challenges and therapeutic complexity of managing CML in the setting of multi-TKI intolerance. Importantly, it underscores the persistent molecular silence despite repeated RT-qPCR testing and the successful introduction of asciminib as a novel therapeutic alternative."

Journal • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Myeloproliferative Neoplasm • Oncology • ABL1 • BCR

PPAR-γ suppresses macrophage senescence and allergic airway inflammation through controlling lipid metabolic pathways. (PubMed, EBioMedicine) - "These findings identify macrophage senescence as a pathogenic driver of allergic airway inflammation and establish PPAR-γ as a critical regulator of macrophage senescence and homoeostasis, highlighting its potential as a therapeutic target for asthma."

Journal • Asthma • Immunology • Inflammation • Metabolic Disorders • Pulmonary Disease • Respiratory Diseases • CD36 • CDKN2A • FABP4 • ICAM1 • IL4 • IL5 • IL6 • ITGAX • PPARG • SCARB1 • TIMP1 • TNFA

IPACE-HIV: Improving Physical Ability and Cellular Senescence Elimination in HIV (clinicaltrials.gov) - P2 | N=82 | Active, not recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting ➔ Active, not recruiting

Enrollment closed • Human Immunodeficiency Virus • Infectious Disease

A Phase I/II Trial of Ruxolitinib with Chemotherapy for Patients with Relapsed and/or Refractory Philadelphia-like Acute Lymphoblastic Leukemia. (PubMed, Clin Lymphoma Myeloma Leuk) - P2 | "Continued efforts should focus on identifying optimal treatment strategies for this high-risk group of patients."

Journal • P1/2 data • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • CRLF2 • EPOR • HMBOX1 • JAK2 • NUP214

A phase I study of asciminib in combination with dasatinib, prednisone, and blinatumomab for Ph-positive acute leukemia in adults. (ASCO 2025) - P1 | "Dual ABL1 inhibition with ASC and DAS can be safely combined with blin in Ph+ acute leukemia. An additional 25-pt cohort is planned with blin in combination with DAS and ASC at optimized doses. Response kinetics."

Clinical • Combination therapy • P1 data • Acute Lymphocytic Leukemia • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • Respiratory Diseases • IKZF1

Dasatinib and CAR T-Cell Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Nonrandomized Clinical Trial. (PubMed, JAMA Oncol) - P2 | "Dasatinib was administered with a 2-week vindesine and dexamethasone regimen as induction, followed by sequential CD19 and CD22 CAR T-cell therapies and single-agent dasatinib maintenance. The primary end point was CMR rate after CD19 CAR T-cell therapy...Further studies with larger cohorts and longer follow-up durations are needed. ClinicalTrials.gov Identifier: NCT04788472."

Clinical • Journal • Acute Lymphocytic Leukemia • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • CD22

Dasatinib is superior to imatinib in adult Ph + ALL: a propensity score-matched analysis of pooled JALSG trial data. (PubMed, Int J Hematol) - "Although the 3-year cumulative incidence of relapse tended to be lower with dasatinib (18 vs. 40%, P = 0.07), non-relapse mortality was comparable between groups (8.8 vs. 12%, P = 0.33). This analysis demonstrates improved survival with dasatinib-based therapy in adult Ph + ALL, informing tyrosine kinase inhibitor selection in treatment planning."

Journal • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • Transplantation

Primary efficacy analysis of phase II study investigating tyrosine kinase inhibitor (TKI) and inotuzumab ozogamicin-based therapy for newly diagnosed Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) (ASH 2025) - "Tyrosine kinase inhibitor (TKI) + blinatumomab regimenshave demonstrated high MR4 rates and favorable overall survival (OS); however, these regimens includeup to 5 courses of blinatumomab which is a continuous 28-day infusion (Kantarjian et al, JCO 2024; Foa etal, JCO 2024)...Eligibilitycriteria includes newly diagnosed Ph+ ALL, age ≥ 18, ECOG ≤2, CD22+ on ≥20% blasts, and no centralnervous system (CNS) disease.Schema 1 was as follows; Course (C) 1 was (28 days) dasatinib (DAS) 140mg daily, dexamethasone (dex)10mg/m2 D1-7 & D15-21, and InO 0.8mg/m2 D8, 0.5mg/m2 D15 and D22...If MR4 was not achieved by end of C2 (EOC2), DAS was switched to ponatinib(PON)...TKI + InO-based therapy for newly diagnosed pts with Ph+ ALL has an MR3+ rate of 81% within 2 coursesand 100% of pts achieved MR4 and/or NGS MRD- disease by EOC3. No cases of VOD were seen withSchema 2. Given the excellent rates of MR3+ with limited cycles of InO, further development of thisinduction approach is..."

Clinical • P2 data • Acute Lymphocytic Leukemia • CNS Disorders • Hematological Malignancies • Hepatology • Infectious Disease • Leukemia • Pulmonary Disease • Respiratory Diseases • Septic Shock • IKZF1

PHASE 3 STUDY OF INTENSIVE CHEMOTHERAPY WITH OR WITHOUT DASATINIB IN PATIENTS WITH CORE-BINDING FACTOR ACUTE MYELOID LEUKEMIA – FINAL ANALYSIS OF THE AMLSG 21-13 TRIAL (EHA 2025) - P3 | "Two previous phase 1b/2 trials in CBF-AML have shown the combination of chemotherapy with dasatinib to be safe and associated with favorable outcome.Aims: We present results from the final analysis of the randomized, open-label, phase 3 trial of intensive chemotherapy with or without dasatinib in adult patients with CBF-AML (NCT02013648).Patients received "3+7" induction therapy (optional 2nd cycle if PR only after the 1st cycle), followed by 4 cycles of high-dose cytarabine 3 g/m2 (>60 years: 1 g/m2) q12h, days 1-3; in the investigational arm, patients received dasatinib 100 mg QD on days 8-21 in induction, and on days 4-28 in consolidation cycles, followed by single-agent dasatinib 100 mg QD for one year (or until relapse). In patients with CBF-AML, the addition of dasatinib to intensive chemotherapy failed to improve EFS and OS overall as well as in patient subgroups. The frequency of adverse events was higher in the investigational arm."

Clinical • P3 data • Acute Kidney Injury • Acute Myelogenous Leukemia • Atrial Fibrillation • Cardiovascular • Febrile Neutropenia • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Nephrology • Neutropenia • Oncology • Pneumonia • Renal Disease • Respiratory Diseases • Septic Shock • KIT • RUNX1 • RUNX1T1

Age-dependent neuro-immune changes in glioblastoma shape therapeutic response and reveal senescent microglia as a targetable vulnerability (AACR 2026) - "Mice received brain radiation, anti-PD-1, and IDO enzyme inhibition, alone ± senolytics (dasatinib+quercetin) or AP compound-induced clearance p16INK4A+ senescent cells. A human GBM aging model was developed by depleting CD4+, CD8+, CD19+, and NK1.1+ cells in young and aged C57BL/6 mice, prior to patient-derived GBM43 (PDX) intracranial engraftment, followed by SOC radiotherapy + temozolomide ± senolytics. Transcriptomic profiling showed minimal age-related changes in tumor core but marked alterations in older PT tissues... The PT brain is a key site of age-dependent immune dysfunction in GBM. Senescent microglia may create an immunosuppressive niche that limits the immunotherapy efficacy in older adults. Senolytics may restore treatment efficacy and improve outcomes in older GBM hosts."

Brain Cancer • Glioblastoma • Oncology • Solid Tumor • CD4 • CD8 • CDKN2A

Senolytic treatment induces oligodendrocyte dysfunction and demyelination in the corpus callosum. (PubMed, Proc Natl Acad Sci U S A) - "Initial data showed that naïve young (3 to 4 mo) and aged (22 mo) C57BL6/J mice treated with dasatinib and quercetin (D+Q) developed significant demyelination compared to vehicle-treated controls, though no cell death was observed in the brain...Due to the resemblance between oligodendrocytes treated with D+Q and those found in MS lesions, D+Q treatment offers a potential method to model an aspect of oligodendrocyte dysfunction relevant to MS. Therefore, understanding the mechanism by which D+Q perturb oligodendrocyte function may provide insight into some of the pathological features contributing to disease progression in MS."

Journal • CNS Disorders • Multiple Sclerosis • Solid Tumor • MBP

Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects (clinicaltrials.gov) - P2/3 | N=160 | Recruiting | Sponsor: Cedars-Sinai Medical Center | Trial completion date: Feb 2027 ➔ Feb 2028 | Trial primary completion date: Feb 2026 ➔ Feb 2027

Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia. (PubMed, Blood) - P1 | "Dual BCR::ABL1 inhibition with dasatinib and asciminib is safe with encouraging activity in patients with de novo Ph+ ALL. ClinicalTrials.gov NCT02081378."

Journal • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Chronic Myeloid Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • Pancreatitis • Transplantation

Resistance to the SFK inhibitor NXP900 in cholangiocarcinoma is characterized by IL13RA2-AKT signaling and can be overcome by combination therapy (AACR 2026) - "NXP900 is a highly selective SFK inhibitor with a novel mechanism of action that locks SFKs in a closed, inhibited conformation, providing sustained suppression of catalytic and non-catalytic functions, which is distinct from other SFK inhibitors like dasatinib. These findings confirm the central role of IL13RA2 signaling and the PI3K-AKT pathway in mediating acquired resistance to NXP900, consistent with our previous multiomics analysis. Importantly, this study identifies combination strategies that may be able to overcome NXP900 resistance, supporting the development of combinatorial approaches to restore therapeutic efficacy in resistant tumors."

Combination therapy • Biliary Cancer • Cholangiocarcinoma • Oncology • Solid Tumor • IL13RA2

Targeted modulation of the blood-tumor barrier enhances drug delivery and survival in glioblastoma models (AACR 2026) - "This molecular modulation disrupts endothelial barrier integrity, demonstrated by reduced trans-endothelial electrical resistance and increased dextran permeability in vitro, as well as enhanced intratumoral sodium fluorescein and cisplatin accumulation in vivo in murine GBM xenograft models. Collectively, these findings position targeted BTB modulation as a promising therapeutic strategy. Leveraging both novel agents such as BIA and repurposed FDA-approved drugs like dasatinib may significantly enhance drug delivery, improve therapeutic outcomes, and ultimately benefit patients with GBM."

Brain Cancer • Glioblastoma • Hematological Malignancies • Oncology • Solid Tumor • ACVRL1 • CD93 • CDH5